2737 | Humans |
1600 | Female |
1448 | Male |
935 | Middle Aged |
863 | Adult |
842 | Animals |
737 | Aged |
377 | Young Adult |
339 | Adolescent |
335 | Treatment Outcome |
305 | Risk Factors |
272 | Aged, 80 and over |
221 | Child |
207 | Mice |
191 | Time Factors |
179 | Prospective Studies |
157 | Follow-Up Studies |
155 | Case-Control Studies |
152 | Prognosis |
150 | Mutation |
143 | Child, Preschool |
138 | Genotype |
135 | Cohort Studies |
134 | Polymorphism, Single Nucleotide |
131 | Genetic Predisposition to Disease |
123 | Phenotype |
122 | Infant |
120 | Double-Blind Method |
118 | Phylogeny |
113 | Genome-Wide Association Study |
110 | Disease-Free Survival |
108 | Retrospective Studies |
95 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
94 | Incidence |
94 | Europe |
94 | Age Factors |
90 | Reproducibility of Results |
90 | Mice, Inbred C57BL |
90 | Ecosystem |
90 | Australia |
87 | Severity of Illness Index |
86 | Practice Guidelines as Topic |
79 | Proportional Hazards Models |
79 | Consensus |
77 | Disease Progression |
76 | Disease Models, Animal |
75 | Surveys and Questionnaires |
75 | Genetic Variation |
72 | Breast Neoplasms (genetics) |
71 | Pregnancy |
71 | Infant, Newborn |
70 | Survival Rate |
70 | Molecular Sequence Data |
69 | Risk Assessment |
69 | Kaplan-Meier Estimate |
68 | Prevalence |
66 | Sequence Analysis, DNA |
65 | Signal Transduction |
65 | Risk |
65 | Neoplasm Staging |
65 | Cross-Sectional Studies |
65 | Biodiversity |
65 | Antineoplastic Agents (therapeutic use) |
63 | Algorithms |
60 | Models, Biological |
60 | Amino Acid Sequence |
59 | Models, Theoretical |
57 | Evolution, Molecular |
56 | Mice, Knockout |
56 | Alleles |
55 | Survival Analysis |
55 | Registries |
54 | Odds Ratio |
54 | Drug Administration Schedule |
54 | Cell Line, Tumor |
54 | Biological Evolution |
53 | Randomized Controlled Trials as Topic |
53 | International Cooperation |
51 | Societies, Medical |
51 | Polymorphism, Single Nucleotide (genetics) |
51 | Multivariate Analysis |
51 | Global Health |
51 | Europe (epidemiology) |
50 | Gene Expression Profiling |
49 | Quality of Life |
49 | Predictive Value of Tests |
49 | Pedigree |
48 | Species Specificity |
48 | Genetic Association Studies |
48 | Drug Therapy, Combination |
48 | Cells, Cultured |
48 | Body Mass Index |
48 | Biomarkers (blood) |
46 | Longitudinal Studies |
46 | Breast Neoplasms (pathology) |
45 | Sex Factors |
45 | European Continental Ancestry Group (genetics) |
45 | Cell Line |
44 | Terminology as Topic |
44 | Mutation (genetics) |
44 | France |
44 | Combined Modality Therapy |
44 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
43 | Magnetic Resonance Imaging |
43 | Internationality |
42 | Dose-Response Relationship, Drug |
41 | Sensitivity and Specificity |
40 | Models, Molecular |
40 | Genetic Predisposition to Disease (genetics) |
39 | Australia (epidemiology) |
38 | Recurrence |
38 | Logistic Models |
38 | Comorbidity |
37 | Seasons |
37 | Rats |
37 | Disease Management |
36 | Neoplasm Metastasis |
36 | Gene Expression Regulation |
36 | Computer Simulation |
36 | Climate Change |
36 | Chromosome Mapping |
35 | Base Sequence |
34 | Temperature |
34 | Protein Binding |
33 | Breast Neoplasms (drug therapy) |
33 | Antineoplastic Agents (adverse effects) |
32 | Research Design |
32 | Evidence-Based Medicine |
32 | Clinical Trials as Topic |
32 | Biomechanical Phenomena |
31 | United States |
31 | Protein Kinase Inhibitors (therapeutic use) |
31 | Mice, Transgenic |
31 | Melanoma (drug therapy) |
31 | Immunohistochemistry |
31 | DNA Mutational Analysis |
30 | Transcription Factors (genetics) |
30 | Models, Statistical |
30 | Coral Reefs |
29 | Diet |
29 | Climate |
29 | Antiviral Agents (therapeutic use) |
28 | Software |
28 | Heterozygote |
28 | Bayes Theorem |
28 | Age of Onset |
27 | Skin Neoplasms (pathology) |
27 | Outcome Assessment (Health Care) |
27 | Melanoma (pathology) |
27 | High-Throughput Nucleotide Sequencing |
27 | HIV Infections (drug therapy) |
27 | HEK293 Cells |
27 | Environment |
27 | Breast Neoplasms (metabolism) |
27 | Administration, Oral |
26 | Ovarian Neoplasms (pathology) |
26 | Genomics |
26 | Databases, Factual |
25 | Signal Transduction (genetics) |
25 | Life Style |
25 | Intensive Care Units |
25 | Intellectual Disability (genetics) |
25 | Gene Frequency |
25 | Gene Expression |
24 | Protein Kinase Inhibitors (adverse effects) |
24 | Neoplasm Grading |
24 | Models, Genetic |
24 | Guidelines as Topic |
24 | Equipment Design |
24 | Electromyography |
24 | Chronic Disease |
24 | Brain (pathology) |
23 | Transcriptome |
23 | Socioeconomic Factors |
23 | Quantitative Trait Loci |
23 | Plant Proteins (genetics) |
23 | Ovarian Neoplasms (genetics) |
23 | Muscle, Skeletal (physiology) |
23 | Hepatitis C, Chronic (drug therapy) |
23 | Conservation of Natural Resources (methods) |
23 | Cluster Analysis |
23 | Antibodies, Monoclonal (therapeutic use) |
22 | Real-Time Polymerase Chain Reaction |
22 | RNA, Messenger (genetics) |
22 | Protein Transport |
22 | Protein Conformation |
22 | Oceans and Seas |
22 | Melanoma (genetics) |
22 | Genetic Loci |
22 | Gene Expression Regulation, Plant |
22 | Gene Expression Regulation, Neoplastic |
22 | Critical Illness |
22 | Computational Biology |
22 | Chemotherapy, Adjuvant |
21 | Tomography, X-Ray Computed |
21 | Regression Analysis |
21 | RNA, Messenger (metabolism) |
21 | Pilot Projects |
21 | Neuropsychological Tests |
21 | Linear Models |
21 | Genetics, Population |
21 | Flow Cytometry |
21 | Exercise (physiology) |
21 | Conservation of Natural Resources |
21 | Cell Differentiation |
21 | Breast Neoplasms (epidemiology) |
21 | Biomass |
21 | Antineoplastic Agents (administration & dosage) |
21 | Acute Disease |
20 | Survival Rate (trends) |
20 | Stress, Physiological |
20 | Risk Assessment (methods) |
20 | Remission Induction |
20 | Prosthesis Design |
20 | Population Dynamics |
20 | Observer Variation |
20 | Neoplasms (pathology) |
20 | Neoplasms (drug therapy) |
20 | Mutation, Missense |
20 | Membrane Proteins (genetics) |
20 | Hospital Mortality |
20 | Haplotypes |
20 | Feeding Behavior |
20 | Cooperative Behavior |
20 | Antineoplastic Combined Chemotherapy Protocols (administration & dosage) |
20 | Anti-Bacterial Agents (therapeutic use) |
20 | Analysis of Variance |
19 | Reverse Transcriptase Polymerase Chain Reaction |
19 | Plant Proteins (metabolism) |
19 | Phosphorylation |
19 | Neoplasms (epidemiology) |
19 | Meta-Analysis as Topic |
19 | Imidazoles (administration & dosage) |
19 | Hydrogen-Ion Concentration |
19 | Hepacivirus (genetics) |
19 | Geography |
19 | France (epidemiology) |
19 | Exercise |
19 | Electrocardiography |
19 | Databases, Genetic |
19 | DNA, Mitochondrial (genetics) |
19 | DNA Methylation |
19 | Blotting, Western |
19 | Binding Sites |
19 | Antibodies, Monoclonal, Humanized (therapeutic use) |
18 | Viral Load |
18 | United Kingdom |
18 | Stroke (epidemiology) |
18 | Sequence Alignment |
18 | Running (physiology) |
18 | Patient Selection |
18 | Medical Oncology |
18 | Magnetic Resonance Imaging (methods) |
18 | Lung Neoplasms (pathology) |
18 | Host-Pathogen Interactions |
18 | Health Knowledge, Attitudes, Practice |
18 | Genome, Human (genetics) |
18 | Exome (genetics) |
18 | DNA-Binding Proteins (genetics) |
18 | Colorectal Neoplasms (genetics) |
18 | Cattle |
18 | Cardiovascular Diseases (prevention & control) |
18 | Brain (metabolism) |
18 | Biomarkers, Tumor (genetics) |
18 | Antineoplastic Agents (pharmacology) |
17 | Transcription Factors (metabolism) |
17 | Stroke (etiology) |
17 | Skin Neoplasms (genetics) |
17 | Skin Neoplasms (drug therapy) |
17 | Signal Transduction (drug effects) |
17 | Neoplasm Recurrence, Local (drug therapy) |
17 | Mitochondria (metabolism) |
17 | Mice, Inbred BALB C |
17 | Kinetics |
17 | Genome, Plant |
17 | Fossils |
17 | Exercise Test |
17 | Drug Combinations |
17 | Colorectal Neoplasms (pathology) |
17 | Cell Proliferation |
17 | Cardiovascular Diseases (epidemiology) |
17 | Body Weight |
17 | Biopsy |
17 | Athletes |
17 | Antibodies, Monoclonal, Humanized (administration & dosage) |
17 | Aging (physiology) |
17 | Age Distribution |
16 | Transcription, Genetic |
16 | T-Lymphocytes (immunology) |
16 | Sex Distribution |
16 | Sex Characteristics |
16 | Reference Values |
16 | ROC Curve |
16 | Phylogeography |
16 | Molecular Sequence Annotation |
16 | Hypoglycemic Agents (therapeutic use) |
16 | History, Ancient |
16 | Germ-Line Mutation |
16 | Genomics (methods) |
16 | Genome-Wide Association Study (methods) |
16 | Enzyme-Linked Immunosorbent Assay |
16 | Droughts |
16 | Body Size |
16 | Blood Glucose (metabolism) |
16 | Biomarkers (metabolism) |
16 | Athletic Performance (physiology) |
16 | Asian Continental Ancestry Group (genetics) |
16 | Animal Distribution |
15 | Vaccination |
15 | Sulfonamides (therapeutic use) |
15 | Structure-Activity Relationship |
15 | Social Behavior |
15 | Receptor, ErbB-2 (metabolism) |
15 | Rats, Wistar |
15 | Quantitative Trait Loci (genetics) |
15 | Protein Kinase Inhibitors (administration & dosage) |
15 | Postmenopause |
15 | Positron-Emission Tomography |
15 | Polymerase Chain Reaction |
15 | Plant Leaves (metabolism) |
15 | Neoplasms (therapy) |
15 | Neoplasms (genetics) |
15 | Muscle, Skeletal (physiopathology) |
15 | Multiple Myeloma (drug therapy) |
15 | Monte Carlo Method |
15 | Melanoma (mortality) |
15 | MCF-7 Cells |
15 | Injections, Subcutaneous |
15 | Forecasting |
15 | Diagnosis, Differential |
15 | Diabetes Mellitus, Type 2 (drug therapy) |
15 | Developing Countries |
15 | Delphi Technique |
15 | Cost-Benefit Analysis |
15 | Cause of Death |
15 | Brain (diagnostic imaging) |
15 | Bone Neoplasms (secondary) |
15 | Blood Pressure |
15 | BRCA1 Protein (genetics) |
14 | Water |
14 | United States (epidemiology) |
14 | Repressor Proteins (genetics) |
14 | Rats, Sprague-Dawley |
14 | Prostatic Neoplasms (genetics) |
14 | Paclitaxel (administration & dosage) |
14 | Ovarian Neoplasms (therapy) |
14 | Ovarian Neoplasms (drug therapy) |
14 | Organ Size |
14 | Nuclear Proteins (genetics) |
14 | Muscle Contraction (physiology) |
14 | HeLa Cells |
14 | HIV Infections (complications) |
14 | Fishes |
14 | Epigenesis, Genetic |
14 | Diabetes Mellitus, Type 2 (complications) |
14 | Crystallography, X-Ray |
14 | Congresses as Topic |
14 | Clinical Trials, Phase III as Topic |
14 | Carbon Cycle |
14 | Biomarkers, Tumor (metabolism) |
14 | Biomarkers, Tumor (analysis) |
14 | Arabidopsis (metabolism) |
14 | Arabidopsis (genetics) |
14 | Antibodies, Monoclonal (administration & dosage) |
14 | Anti-Bacterial Agents (administration & dosage) |
14 | Adaptation, Physiological |
13 | World Health Organization |
13 | Tumor Suppressor Proteins (genetics) |
13 | Tropical Climate |
13 | Swine |
13 | Selection, Genetic |
13 | Receptors, Estrogen (metabolism) |
13 | Pyrimidines (therapeutic use) |
13 | Proteins (genetics) |
13 | Prostatic Neoplasms, Castration-Resistant (pathology) |
13 | Prostatic Neoplasms (pathology) |
13 | Population Density |
13 | Pain Measurement |
13 | Muscle, Skeletal (metabolism) |
13 | Microbial Sensitivity Tests |
13 | Lung Neoplasms (genetics) |
13 | Light |
13 | Internet |
13 | Homeodomain Proteins (genetics) |
13 | Hepatitis C, Chronic (complications) |
13 | Hematopoietic Stem Cell Transplantation |
13 | Healthy Volunteers |
13 | Health Policy |
13 | Genome |
13 | Genome, Human |
13 | Genetic Variation (genetics) |
13 | Genetic Testing |
13 | Genetic Loci (genetics) |
13 | Gene-Environment Interaction |
13 | Feasibility Studies |
13 | European Continental Ancestry Group |
13 | Elasticity Imaging Techniques |
13 | Computational Biology (methods) |
13 | Cholesterol (metabolism) |
13 | Carrier Proteins (genetics) |
13 | Carbon (metabolism) |
13 | Calcium (metabolism) |
13 | Brain (physiopathology) |
13 | Blood Pressure (physiology) |
13 | Bacterial Proteins (genetics) |
13 | Arthritis, Rheumatoid (drug therapy) |
13 | Arabidopsis Proteins (metabolism) |
13 | Antiviral Agents (adverse effects) |
13 | Antiviral Agents (administration & dosage) |
13 | Antibodies, Monoclonal (adverse effects) |
13 | Amino Acid Substitution |
12 | Syndrome |
12 | Stroke Volume |
12 | Smoking (epidemiology) |
12 | Sheep |
12 | Sequence Analysis, RNA |
12 | Ribavirin (therapeutic use) |
12 | Reference Standards |
12 | Reactive Oxygen Species (metabolism) |
12 | Pyrimidines (administration & dosage) |
12 | Proto-Oncogene Proteins B-raf (genetics) |
12 | Promoter Regions, Genetic |
12 | Practice Guidelines as Topic (standards) |
12 | Oxygen Consumption |
12 | Oxidation-Reduction |
12 | Oligonucleotide Array Sequence Analysis |
12 | North America |
12 | Neurons (metabolism) |
12 | Neoplasms (immunology) |
12 | Neoplasm Recurrence, Local (pathology) |
12 | Neoplasm Invasiveness |
12 | Macrophages (metabolism) |
12 | Liver (metabolism) |
12 | Killer Cells, Natural (immunology) |
12 | Kidney Neoplasms (pathology) |
12 | Immunosuppressive Agents (therapeutic use) |
12 | Imidazoles (therapeutic use) |
12 | Imaging, Three-Dimensional |
12 | Hypertension, Pulmonary (physiopathology) |
12 | Hospitalization |
12 | Hepatitis C, Chronic (virology) |
12 | Hemodynamics |
12 | Glucose (metabolism) |
12 | Global Health (trends) |
12 | Genetic Markers |
12 | Forests |
12 | Food Chain |
12 | Extinction, Biological |
12 | Estrogen Receptor alpha (genetics) |
12 | Electroencephalography |
12 | Dendritic Cells (immunology) |
12 | Cost of Illness |
12 | Consensus Development Conferences as Topic |
12 | Cognition |
12 | Cholesterol, LDL (blood) |
12 | Cell Proliferation (drug effects) |
12 | Cardiovascular Diseases (blood) |
12 | Breast Neoplasms (mortality) |
12 | Brain (physiology) |
12 | Biomarkers |
12 | Bacterial Proteins (metabolism) |
12 | Area Under Curve |
12 | Antibodies, Monoclonal, Humanized (adverse effects) |
12 | Anti-HIV Agents (therapeutic use) |
12 | Administration, Intravenous |
11 | Up-Regulation |
11 | Triticum (genetics) |
11 | T-Lymphocytes, Regulatory (immunology) |
11 | Stroke (therapy) |
11 | Stroke (drug therapy) |
11 | Stents |
11 | Statistics as Topic |
11 | Soil (chemistry) |
11 | Smoking (adverse effects) |
11 | Reproduction |
11 | Radiography |
11 | Proteomics |
11 | Prostatic Neoplasms, Castration-Resistant (drug therapy) |
11 | Polymorphism, Genetic |
11 | Polyethylene Glycols (administration & dosage) |
11 | Plant Leaves (physiology) |
11 | New Zealand (epidemiology) |
11 | Nerve Tissue Proteins (genetics) |
11 | Melanoma (secondary) |
11 | Lymphocyte Activation |
11 | Lymphatic Metastasis |
11 | Liver (pathology) |
11 | Lipids (blood) |
11 | Introduced Species |
11 | International Agencies |
11 | Indoles (administration & dosage) |
11 | In Situ Hybridization, Fluorescence |
11 | Imidazoles (adverse effects) |
11 | Hot Temperature |
11 | Host-Parasite Interactions |
11 | Homozygote |
11 | High-Throughput Nucleotide Sequencing (methods) |
11 | Health Services Accessibility |
11 | Global Health (statistics & numerical data) |
11 | Genes, BRCA2 |